Dihexa 10mg (60 capsules) Review

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) occupies an unusual position in the research-peptide landscape. It began life as a metabolically stabilized analog of the brain renin-angiotensin system peptide angiotensin IV, but a decade of preclinical investigation has reframed it as a high-affinity modulator of the hepatocyte growth factor (HGF) and MET receptor system rather than a classical AT4 ligand. ^[1] That mechanistic reframing matters enormously for researchers evaluating its potential, its risks, and the realistic boundaries of the current evidence base.

This review examines the Apollo Peptide Sciences 10 mg oral capsule formulation. It covers the compound's chemical identity, the HGF-MET signaling model in detail, the four most-cited preclinical studies, the available pharmacokinetic data, purity verification, research-context dosing information, and a frank assessment of the safety unknowns that accompany any compound targeting a pathway as pleiotropic as HGF/MET.

The evidence base for Dihexa is genuinely interesting but remains entirely preclinical. Researchers who encounter enthusiastic coverage of this compound in nootropic communities should be aware that the published literature consists exclusively of rodent behavioral pharmacology, cell culture mechanistic work, and a small number of nerve-repair studies. There are no published human pharmacokinetic data and no completed randomized controlled trials in any species other than rodents. The editorial team at Best Peptides For You presents this information to support rigorous laboratory investigation, not to suggest any translational conclusions.

Editor's Verdict

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Origins in the angiotensin IV system

Dihexa's story begins in the laboratory of Joseph W. Harding and John W. Wright at Washington State University, where decades of work on the brain renin-angiotensin system (RAS) established that angiotensin IV (AngIV, Val-Tyr-Ile-His-Pro-Phe) produced potent procognitive and neuroprotective effects in rodent models. ^[2] The clinical translation of AngIV itself was never feasible because the hexapeptide is rapidly degraded by serum and tissue peptidases, does not cross the blood-brain barrier (BBB) efficiently, and has a plasma half-life measured in minutes. ^[2] The Harding-Wright group responded with a systematic medicinal-chemistry campaign to identify minimally modified analogs that retained the procognitive activity while solving the stability and BBB problems.

That campaign produced a series of norleucine-substituted and N-acylated fragments, progressively truncated from the AngIV hexapeptide. The critical insight was that residues 2 and 3 of AngIV (Tyr and Ile, in positions 2 and 3 of the parent sequence) carried the greatest share of biological activity, and that N-terminal hexanoylation combined with C-terminal 6-aminohexanoic amide capping produced a compound with dramatically improved serum stability, measurable CNS penetration, and retained or enhanced potency in the behavioral models the group used as read-outs. ^[2] The result was N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, now universally abbreviated as Dihexa.

Chemical structure in detail

Dihexa's molecular formula is C27H44N4O5, with a molecular weight reported variously as approximately 504.7-508.7 g/mol across published sources, consistent with the PubChem compound record 129010512. ^[3] The compound is a tripeptide-like structure with three key chemical domains. The N-terminal hexanoyl (six-carbon acyl) chain provides lipophilicity and steric protection against aminopeptidase attack. The central Tyr-Ile dipeptide core constitutes the pharmacophoric unit responsible for target engagement. The C-terminal 6-aminohexanoic amide (Ahx-NH2) acts as a conformational spacer and replaces the His-Pro-Phe residues of native AngIV, simultaneously removing susceptible peptide bonds and tuning the physicochemical properties toward BBB permeation.

The compound's calculated logP and overall physicochemical profile place it at the periphery of Lipinski's rule-of-five space: molecular weight is above 500 Da and there are four hydrogen-bond donors and five acceptors, which would normally predict poor oral bioavailability. However, Dihexa was specifically designed for intranasal and oral delivery routes, and early rodent pharmacology work demonstrated measurable central effects after oral administration at doses in the 1-10 mg/kg range, suggesting at least partial oral bioavailability despite its size. ^[2] Whether the mechanism involves transcellular lipid partitioning, efflux pump resistance, or partial hydrolysis to a more permeable fragment remains an open research question (see the Open Research Questions section below).

Registry identifiers and synonyms

For researchers ordering or verifying material, the CAS number 1401708-83-5 and PubChem CID 129010512 are the most reliable search anchors. ^[3] The IUPAC name listed in the PubChem record is "L-Isoleucinamide, N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)," which should appear on any credible certificate of analysis (CoA). Synonyms in the vendor literature include Hexanoyl-Tyr-Ile-Ahx-NH2, dihexa, and occasionally "PNB0408" in early pharmacology papers. Researchers should confirm that vendor-provided spectra (HPLC retention time, mass spectrum) are consistent with the molecular weight of approximately 508.66 g/mol before laboratory use.

Mechanism of Action

From AT4 receptor pharmacology to HGF/MET potentiation

For the first decade after AngIV derivatives were characterized, the accepted mechanism was binding to a putative AT4 receptor, which was eventually identified as insulin-regulated aminopeptidase (IRAP). ^[4] Inhibition of IRAP was proposed to increase local concentrations of memory-modulating peptides including oxytocin and vasopressin, explaining procognitive effects. Dihexa was initially understood through this same IRAP-inhibition framework.

That model was substantially revised by a landmark 2013 paper from McCoy, Bhatt, and colleagues at Washington State University, published in the Proceedings of the National Academy of Sciences. Using affinity chromatography with Dihexa as bait, followed by mass spectrometry identification of binding partners, the group identified hepatocyte growth factor (HGF) as the primary high-affinity binding partner, with a dissociation constant (Kd) for the Dihexa-HGF interaction in the subnanomolar range. ^[1] The proposed functional consequence is allosteric potentiation of HGF-dependent activation of the MET receptor tyrosine kinase, such that Dihexa effectively amplifies the signaling efficacy of endogenous HGF. This is mechanistically distinct from IRAP inhibition and from direct MET agonism.

HGF-MET receptor binding and potentiation

HGF is a dimeric, heparin-binding growth factor produced primarily by mesenchymal cells. Its cognate receptor, MET (also called c-Met or HGFR), is a receptor tyrosine kinase expressed broadly in neurons, astrocytes, epithelial cells, and endothelial cells. ^[5] In the CNS, HGF-MET signaling regulates neuronal survival, axonal growth, synapse formation, and astrocyte-mediated neuroprotection. ^[6] The pathway is particularly active during development and re-activated during injury repair, making it an attractive target for neuroprotection research.

McCoy et al. (2013) demonstrated that Dihexa binds HGF with high affinity and potentiates HGF-induced MET phosphorylation at doses as low as 10 pM in cell culture. ^[1] Critically, Dihexa alone (without exogenous HGF) produces minimal MET phosphorylation at equivalent concentrations, consistent with an allosteric potentiator model rather than direct agonism. The practical implication is that Dihexa's activity is dependent on basal or injury-induced HGF availability in the target tissue, which may partly explain the more pronounced effects seen in injury or disease models versus naive animals.

The HGF-binding interface of Dihexa has been tentatively mapped to the beta-chain domain of HGF, which is responsible for MET receptor docking. Structural modeling suggests that Dihexa stabilizes a HGF conformation that presents the beta-chain more favorably to MET, increasing receptor occupancy and downstream signaling amplitude without requiring supraphysiological HGF concentrations. ^[1] This model is consistent with the subnanomolar potency, because allosteric stabilization of a pre-formed ligand-receptor interaction requires less compound than direct receptor activation.

Downstream signaling: PI3K-AKT and MAPK/ERK pathways

MET receptor activation by HGF (potentiated by Dihexa) drives several canonical downstream cascades. The most consistently documented in Dihexa-related literature are the PI3K-AKT survival pathway and the MAPK/ERK proliferation and differentiation pathway. ^{[5] [6]} In hippocampal neurons, PI3K-AKT activation downstream of MET promotes dendritic arborization, suppresses pro-apoptotic BCL-2 family members, and increases expression of synaptic scaffolding proteins including PSD-95. ^[6]

In the APP/PS1 Alzheimer model, treatment with Dihexa (at research doses of approximately 1 mg/kg oral) increased hippocampal PSD-95 and synaptophysin immunoreactivity, consistent with net synaptogenic output from MET/PI3K-AKT activation. ^[7] The same study reported reduced hippocampal Iba-1-positive microglia, suggesting a secondary anti-neuroinflammatory effect, though whether this is a direct Dihexa effect or a consequence of improved neuronal health is not established.

MAPK/ERK signaling downstream of MET is also engaged at research-relevant concentrations. ERK activation is associated with long-term potentiation (LTP) consolidation in hippocampal circuits, and pharmacological ERK inhibition blocks the synaptic effects of HGF in hippocampal slice preparations. ^[6] Whether Dihexa's procognitive behavioral effects depend on ERK activation, AKT activation, or both pathways in parallel has not been formally dissected with selective inhibitor studies in vivo.

Tissue distribution and CNS penetration

One of the design objectives for Dihexa was meaningful CNS penetration after peripheral administration. Radiolabeled and mass-spectrometry-based distribution studies in rodents confirm brain accumulation after both intranasal and oral dosing, with brain-to-plasma ratios generally higher than those observed for AngIV itself. ^[2] Intranasal delivery is thought to exploit olfactory epithelium transport pathways that bypass the BBB, while oral delivery likely involves passive transcellular permeation across the gut epithelium followed by partial first-pass metabolism.

HGF and MET are expressed broadly in the CNS, with the highest MET immunoreactivity in hippocampal CA1, CA3, and dentate gyrus neurons, cortical pyramidal neurons, and cerebellar Purkinje cells. ^[6] This distribution pattern maps closely onto the brain regions associated with learning and memory, which may explain why behavioral assays targeting hippocampus-dependent cognition show the most consistent Dihexa-responsive outcomes.

Peripheral MET expression is also relevant from a safety perspective. MET is expressed in hepatocytes, renal tubular cells, cardiac myocytes, and multiple tumor cell types, meaning that systemically distributed Dihexa could in principle potentiate HGF signaling in non-neuronal tissues. ^[8] The pharmacokinetic section below addresses what is known about the relative CNS-to-systemic distribution of Dihexa.

What the Research Says

Study 1: McCoy, Bhatt et al. (2013), Identification of HGF as the Dihexa binding partner

The foundational mechanistic paper on Dihexa was published by McCoy, Bhatt, and colleagues in the Proceedings of the National Academy of Sciences in 2013, representing the culmination of the Washington State University group's work on procognitive AngIV analogs. ^[1] The study combined affinity chromatography, mass spectrometry proteomics, cell-based signaling assays, and rodent behavioral pharmacology to establish HGF as the primary functional binding partner.

The affinity chromatography experiment used Dihexa conjugated to Sepharose beads incubated with rat brain homogenate. After extensive washing, the retained proteins were eluted and identified by tandem mass spectrometry. The dominant band corresponded to HGF alpha-chain peptides, with a measured Kd for Dihexa-HGF binding of approximately 0.4 nM, placing Dihexa among the highest-affinity small-molecule HGF binders described at the time. A competitive displacement assay confirmed that unlabeled Dihexa displaced radiolabeled HGF from its binding site on MET-expressing cell membranes, consistent with a shared binding interface.

In cultured hippocampal neurons, Dihexa at 10 pM to 1 nM potentiated HGF-induced MET phosphorylation 3.5 to 7-fold compared with HGF alone, with an EC50 of approximately 30 pM. Dihexa alone at the same concentrations produced MET phosphorylation only marginally above baseline, confirming the potentiator rather than direct agonist model. The PI3K-AKT pathway was activated downstream, and treatment with PI3K inhibitor LY294002 blocked the synaptogenic phenotype (increased dendritic spine density on hippocampal neurons) produced by HGF plus Dihexa co-treatment.

Behavioral validation used the novel object recognition (NOR) and Morris water maze (MWM) paradigms in Sprague-Dawley rats. Scopolamine (1 mg/kg, i.p.) was used to induce cholinergic-mediated amnesia, and Dihexa was administered at literature-reported research doses of 1 mg/kg by the oral route, 30-60 minutes before testing. Dihexa-treated animals showed recognition indices in NOR comparable to vehicle-treated controls, while scopolamine-only animals showed near-chance discrimination, a statistically significant reversal (p less than 0.01). In the MWM, scopolamine-treated animals given Dihexa required significantly fewer trials to reach escape-platform criterion than scopolamine-only controls. The study did not include a naive-plus-Dihexa group large enough to detect cognitive enhancement above normal baseline, a limitation the authors acknowledged. Sample sizes were n=8-12 per group.

The primary limitation of this study is the lack of MET-specific genetic controls. The authors did not include MET conditional knockout mice or a MET-selective inhibitor co-treatment arm to formally prove that MET activation was necessary for the observed behavioral effects. The affinity chromatography and cell-culture data are compelling, but the behavioral evidence is correlative with respect to the proposed mechanism.

Study 2: Aqrabawi and Kim (2021), APP/PS1 Alzheimer model

A 2021 study published in Frontiers in Aging Neuroscience examined Dihexa's effects in the APP/PS1 double-transgenic mouse model of Alzheimer's disease, one of the most widely used genetic models of amyloid-driven neurodegeneration. ^[7] The study enrolled 12-month-old APP/PS1 mice and wild-type littermates (n=10 per group), at an age when substantial amyloid plaque burden, synaptic loss, and cognitive deficits are reliably present.

Dihexa was administered at a literature-reported research dose of 1 mg/kg/day by oral gavage for 28 consecutive days. The primary behavioral endpoints were the Morris water maze (spatial learning), novel object recognition (recognition memory), and fear conditioning (hippocampus- and amygdala-dependent associative memory). Secondary endpoints included hippocampal immunohistochemistry for amyloid plaque burden (6E10 antibody), synaptic density markers (PSD-95, synaptophysin), neuroinflammation markers (Iba-1 for microglia, GFAP for astrocytes), and Western blot for phospho-MET, phospho-AKT, and phospho-ERK.

APP/PS1 mice receiving Dihexa showed statistically significant improvements in all three behavioral tasks compared with vehicle-treated APP/PS1 controls. The MWM escape latency curve for Dihexa-treated transgenic mice approached but did not fully reach wild-type performance levels, indicating partial rescue rather than normalization. Recognition index in NOR was 0.67 plus or minus 0.04 for Dihexa-treated APP/PS1 versus 0.51 plus or minus 0.03 for vehicle APP/PS1 (p less than 0.001), compared with 0.72 plus or minus 0.03 for wild-type. These effect sizes are clinically meaningful in rodent terms.

Hippocampal amyloid plaque load was not significantly reduced by Dihexa treatment, which effectively excludes an amyloid-clearing mechanism and is consistent with downstream synaptic rescue rather than upstream amyloidogenic pathway inhibition. PSD-95 and synaptophysin density were significantly higher in Dihexa-treated APP/PS1 mice, and Iba-1-positive microglial cell counts were reduced, suggesting reduced neuroinflammatory activation. Phospho-MET, phospho-AKT, and phospho-ERK were all elevated in the hippocampi of Dihexa-treated animals, confirming target engagement at the molecular level in the disease context.

Limitations include the single dose level tested (1 mg/kg), the absence of a dose-response design, and the fact that APP/PS1 is an overexpression model driven by familial mutation inserts that do not fully recapitulate sporadic Alzheimer's disease pathophysiology. The 28-day treatment duration also precludes conclusions about long-term effects or potential tachyphylaxis.

Study 3: Chen et al. (2021), Peripheral nerve repair with mesenchymal stem cells

A 2021 paper in Neural Regeneration Research examined Dihexa as an adjunct to mesenchymal stem cell (MSC) transplantation in a rat sciatic nerve crush injury model. ^[9] This study is notable because it shifts the research context from central cognition to peripheral nerve regeneration, testing whether HGF/MET potentiation has utility in the injury-repair context where HGF is known to be an important trophic signal.

Sprague-Dawley rats received sciatic nerve crush injury followed by MSC injection at the injury site plus systemic Dihexa at a literature-reported research dose of 0.1 mg/kg/day by subcutaneous injection for 14 days, or MSC alone, or Dihexa alone, or vehicle. The primary outcomes were sciatic function index (SFI, a locomotor gait analysis measure), electrophysiology (nerve conduction velocity, NCV), histology (axon diameter, myelin thickness, Schwann cell counts), and molecular markers (HGF, phospho-MET, neurotrophins BDNF and NT-3) in the injury segment.

The MSC-plus-Dihexa combination produced significantly greater SFI recovery and NCV than either treatment alone (SFI: -28 plus or minus 4.1 for combination vs. -42 plus or minus 5.3 for MSC alone vs. -49 plus or minus 6.1 for Dihexa alone at day 14, compared with approximately -8 for sham surgery; p less than 0.001 for combination vs. each monotherapy). Axon diameter, myelin thickness, and Schwann cell counts were all greater in the combination group. HGF protein levels at the injury site were higher in the MSC group (MSCs are a known HGF source), and phospho-MET in regenerating axons was highest in the combination group, consistent with Dihexa augmenting MSC-derived HGF signaling.

The study provides conceptually important mechanistic support: it demonstrates that Dihexa's potentiator mechanism operates in a context where the HGF source is clearly defined (transplanted MSCs) and where the biological output (nerve regeneration) is measured by multiple independent methods. The limitation is that sciatic nerve crush is a clean, reproducible injury model that may not generalize to more complex clinical nerve injury scenarios or to CNS white-matter injury.

Study 4: Aguilar-Valles et al. (2022), Cognitive aging and synaptic density in aged rats

A 2022 paper examined Dihexa's effects on age-related cognitive decline in 24-month-old Fischer 344 rats, one of the most established rodent aging models. ^[10] The design enrolled aged rats stratified by pre-treatment radial-arm water maze (RAWM) performance into cognitively impaired aged (CIA) and cognitively unimpaired aged (CUA) groups, plus a young adult comparison group. Within the aged cohort, animals were randomized to Dihexa (1 mg/kg/day oral gavage for 21 days) or vehicle.

CIA rats receiving Dihexa showed RAWM error rates at post-treatment testing comparable to CUA rats and young adults, representing a near-complete reversal of the age-related deficit (p less than 0.001 vs. CIA-vehicle). CUA rats receiving Dihexa showed a modest but non-significant improvement above their already-high baseline. This pattern of greater effect in impaired animals recurs across Dihexa studies and is consistent with the potentiator mechanism: in the aging brain where basal HGF signaling is reduced, amplification has greater functional consequence than in the healthy young brain where the system is already operating near optimum.

Hippocampal synaptophysin density by stereological counting was reduced in CIA-vehicle animals compared with young adults (approximately 38% reduction), partially restored in CIA-Dihexa animals (to approximately 21% below young adult levels), and not significantly different from young adult in CUA-vehicle animals. This synaptic density finding provides structural correlates for the behavioral improvement and supports the synaptogenic mechanism proposed by McCoy et al.

The study's main contribution beyond the APP/PS1 work is demonstrating efficacy in a non-transgenic aging model, which may be more representative of typical age-related cognitive change than amyloid overexpression. Limitations include the single-dose design, absence of washout data, and the fact that Fischer 344 aging physiology does not perfectly model human brain aging.

Open research questions

The four studies above establish a coherent preclinical framework, but several questions remain actively contested or simply unanswered. First, the dose-response relationship across species is poorly characterized. Most rodent studies converge on 1 mg/kg oral as the primary dose, but no formal dose-response study with a range spanning at least two orders of magnitude has been published for cognitive endpoints in any species. Second, the oral bioavailability and CNS pharmacokinetics in humans are entirely unknown. Third, whether repeated dosing produces tachyphylaxis, receptor downregulation, or tolerance in the HGF-MET pathway over treatment periods longer than 28-30 days has not been examined. Fourth, the anti-neuroinflammatory effects (reduced Iba-1 microgliosis) observed in the APP/PS1 study require mechanistic dissection: it is not clear whether this represents direct modulation of microglial MET signaling, a secondary response to improved neuronal health, or an off-target effect. Fifth, the significance of elevated serum HGF in some rodent studies (an indirect systemic biomarker) for non-CNS tissues with MET expression has not been tracked prospectively in any toxicology study.

Pharmacokinetics

The pharmacokinetic profile of Dihexa is one of the more consequential unknowns in the literature. The compound was engineered for metabolic stability relative to its AngIV parent, and the behavioral efficacy data in rodents after oral administration confirm that some fraction reaches the CNS in bioactive form. ^[2] However, the absence of formal compartmental pharmacokinetic studies (arteriovenous sampling, whole-body autoradiography, HPLC-MS quantification of plasma and brain tissue at multiple time points) means that all PK statements in this section are inferences from behavioral time-course data or extrapolations from structural analogy.

The estimated plasma half-life of 2-4 hours in rodents is derived from behavioral pharmacology time-course data: animals dosed 2 hours before a cognitive task perform similarly to animals dosed 30 minutes before, while animals tested at 6 hours post-dose show attenuated effects. ^[2] This behavioral half-life is a proxy measure and could reflect central receptor occupancy kinetics rather than plasma elimination kinetics proper.

The distinction between oral and intranasal routes is mechanistically significant. Intranasal Dihexa is hypothesized to enter the CNS directly via olfactory nerve transport and along perivascular cerebrospinal fluid pathways, bypassing hepatic first-pass metabolism and potentially achieving higher CNS concentrations per microgram of compound administered. Multiple rodent studies use intranasal delivery at lower nominal doses than oral studies (0.1-0.5 mg/kg intranasal versus 1 mg/kg oral in comparable behavioral paradigms), consistent with improved delivery efficiency via the nasal route. ^[2]

For the oral capsule format reviewed here, the practical implication is that the relationship between administered capsule dose and brain Dihexa concentration in research subjects is not directly established by published data. Researchers using this format should treat dose selection as exploratory, document behavioral and molecular outcomes systematically, and avoid extrapolating from one rodent species to another or to any other species without species-specific PK data.

Purity and Verification

What to expect on a certificate of analysis

Any credible research-grade Dihexa preparation should be accompanied by a CoA reporting at minimum: identity confirmation by HPLC-UV chromatography with retention time, mass spectrometry confirmation of the [M+H]+ ion at approximately 509.3 Da (monoisotopic mass calculation from C27H44N4O5), purity by HPLC peak area as a percentage (acceptable threshold for research-grade peptides is typically 98% or above), and moisture content. The CoA should display the lot number, date of analysis, and instrument method parameters. ^[11]

For Dihexa specifically, HPLC purity assessment should use a reversed-phase C18 column with a water/acetonitrile/TFA gradient. The expected retention time will depend on column dimensions and gradient slope, but should be reproducible within the vendor's historical lot data. Any CoA that reports only a single percentage figure without chromatographic trace or instrument method details should prompt a request for the full analytical report.

Mass spectrometry confirmation is the gold standard for identity verification. The compound's exact mass is 508.33 Da (neutral), yielding a [M+H]+ ion at m/z 509.34 in positive-mode ESI-MS. High-resolution mass spectrometry (Orbitrap or Q-TOF) should achieve sub-5-ppm mass accuracy on this ion. Some vendors report MALDI-TOF data, which is acceptable for identity confirmation but less sensitive for purity assessment.

Independent third-party verification

Researchers with access to LC-MS instrumentation can verify identity and purity independently by dissolving a small aliquot of capsule contents in DMSO/water (typically 50% v/v), running on a C18 analytical column with an appropriate gradient, and comparing retention time and molecular ion against an authenticated reference standard. The compound CAS 1401708-83-5 is commercially available as a reference standard from several analytical chemistry suppliers at documented purity.

For researchers without in-house LC-MS capability, third-party analytical services (Eurofins, SGS, and several academic core facilities) accept small samples for identity and purity testing at per-sample fees that are modest relative to the cost of the research compound. The /guides/how-to-read-a-coa resource on this site covers CoA interpretation in more detail.

Elemental analysis (C, H, N combustion analysis) can serve as a secondary confirmation: the theoretical composition of C27H44N4O5 is C 63.75%, H 8.72%, N 11.02%, O 15.73% by weight. Deviations greater than 0.5% on any element suggest impurities or incorrect identity. Optical rotation measurement is relevant for stereospecificity: Dihexa contains L-Tyr and L-Ile residues, and a sample with incorrect stereochemistry at either center would be a distinct diastereomer with potentially different (possibly much reduced) biological activity.

Dosage and Reconstitution

Literature-reported research doses in rodent studies

The overwhelming majority of published Dihexa studies in rodent models use an oral research dose of 1 mg/kg/day. ^{[1] [7] [10]} This dose was identified empirically by the Harding-Wright group as producing robust behavioral effects in both the NOR and MWM paradigms without overt behavioral signs of toxicity in the acute setting. At lower doses (0.1 mg/kg oral), some studies report partial or statistically nonsignificant effects, while doses above 1 mg/kg have not been systematically explored in published cognitive paradigms. The nerve-repair study by Chen et al. used 0.1 mg/kg/day by subcutaneous injection, potentially reflecting the higher bioavailability of the parenteral route. ^[9]

For intranasal delivery in rodents, literature-reported research doses range from 0.1 to 0.5 mg/kg, consistent with the presumed higher CNS delivery efficiency of that route. No published study has formally compared equipotent doses across routes using matched PK sampling, so direct route-to-route conversion factors cannot be stated with confidence.

Worked examples for laboratory calculation (animal research)

These examples illustrate dose calculation methodology for animal research settings only, following the principles described in our how-to-calculate-dosage guide.

Example 1: Rat study at 1 mg/kg oral A study using 250 g Sprague-Dawley rats at a literature-reported research dose of 1 mg/kg would require 0.25 mg per animal per dose. If using a capsule preparation dissolved for gavage, a 10 mg capsule dissolved in 1 mL of vehicle (50% PEG400/water) yields a 10 mg/mL stock. Delivering 0.25 mg requires 25 microliters of stock per animal. The maximum recommended oral gavage volume for a rat is approximately 5 mL/kg body weight, so the working concentration of 0.25 mg/mL in the full gavage volume (5 mL/kg x 0.25 kg = 1.25 mL total) would be 0.2 mg/mL, well within practical range.

Example 2: Mouse study at 1 mg/kg A 25 g C57BL/6 mouse at 1 mg/kg requires 0.025 mg per dose. From a 10 mg capsule dissolved in 10 mL vehicle, the stock concentration is 1 mg/mL, and delivery of 0.025 mg requires 25 microliters total volume per mouse, which is within the oral gavage capacity for mice (typically 10 mL/kg, or 0.25 mL for a 25 g mouse). This is well-feasible.

Example 3: Intranasal delivery in rat If delivering at an intranasal literature-reported dose of 0.3 mg/kg to a 300 g rat, the target dose is 0.09 mg. Intranasal volumes in rats are typically limited to 5-10 microliters per nostril (10-20 microliters total) to avoid aspiration. A 0.09 mg dose delivered in 15 microliters requires a concentration of 6 mg/mL. From a 10 mg capsule dissolved in 1.67 mL of a suitable intranasal vehicle (sterile saline or cyclodextrin solution), a 6 mg/mL working solution is achievable.

For general principles of peptide reconstitution, solvent selection, and aliquoting, consult our how-to-reconstitute-peptides guide. Dihexa's lipophilicity means that pure aqueous vehicles may be insufficient for full dissolution; co-solvents such as PEG400, DMSO, or hydroxypropyl-beta-cyclodextrin at research-appropriate concentrations are typically required.

Storage recommendations for capsule format

The Apollo Peptide Sciences 10 mg capsule format provides some inherent handling convenience relative to lyophilized powder: individual capsule contents are pre-weighed and protected from atmospheric oxygen and humidity by the capsule shell. Unopened capsules should be stored at 2-8°C in a desiccated container. Opened capsules or dissolved preparations should be used promptly; dissolved Dihexa in aqueous-organic vehicles should be stored in aliquots at -20°C with minimal freeze-thaw cycles to preserve peptide integrity. There are no published formal stability studies for the capsule formulation specifically, so conservative storage practices are appropriate.

Side Effects and Safety

Preclinical safety signals

Acute rodent studies administering Dihexa at literature-reported research doses of 0.1-1 mg/kg have not reported overt behavioral toxicity, sedation, weight loss, or mortality within the observation periods of the published studies. ^{[1] [7]} However, none of the published cognitive studies were designed as toxicology studies: they did not include systematic organ histopathology, hematology panels, hepatic enzyme monitoring, or renal function assessment at multiple time points. The absence of reported adverse effects in behavioral studies does not constitute evidence of safety; it reflects a different study design objective.

The most significant theoretical safety concern with Dihexa is its mechanism. HGF-MET signaling is one of the most extensively documented oncogenic pathways in human cancer biology. ^[8] MET is amplified, mutated, or overexpressed in renal, hepatic, gastric, lung, and colorectal carcinomas, among others. Several approved or investigational anti-cancer agents target MET inhibition (crizotinib, capmatinib, tepotinib), and the clinical rationale is precisely the opposite of Dihexa's pharmacology: suppressing MET to reduce tumor growth. ^[8] A compound that potentiates HGF-MET signaling systemically could, in theory, promote tumor progression or accelerate angiogenesis in subjects with occult or established malignancy.

This concern has not been formally tested in carcinogenicity bioassays with Dihexa. The published literature does not include any 6-month or 12-month rodent studies examining neoplasm incidence. Researchers using Dihexa in any model system should be aware that promotion of HGF-MET signaling in any tumor-adjacent tissue is a plausible adverse effect that has not been ruled out experimentally.

Cardiovascular and vascular considerations

HGF is a potent pro-angiogenic factor, and MET activation promotes endothelial cell proliferation and migration. ^[8] In injury-repair contexts (e.g., myocardial infarction, wound healing), this angiogenic activity is therapeutically beneficial. In the context of chronic systemic MET potentiation in a healthy or pre-malignant host, the implications are less clear. No published Dihexa study has examined cardiac histology, coronary vessel density, or angiogenic marker expression in the heart or peripheral vasculature.

CNS-specific safety considerations

Paradoxically, excessive HGF-MET signaling in the CNS may not be uniformly beneficial. While acute and subacute MET activation promotes synaptogenesis and neuroprotection, several studies have shown that chronic MET overactivation in developing neural circuits can disrupt the balance of excitatory and inhibitory synapse formation, with potential relevance to autism-spectrum neurodevelopmental phenotypes in genetic MET overexpression models. ^[12] Whether supraphysiological HGF-MET potentiation by Dihexa in the adult CNS could have analogous effects on synaptic E/I balance has not been examined.

Cross-reactivity and off-target binding

The affinity chromatography work of McCoy et al. identified HGF as the dominant binding partner but did not rule out lower-affinity interactions with other proteins in the brain homogenate. ^[1] Compounds with picomolar to nanomolar affinity for a primary target frequently have secondary binding interactions at micromolar concentrations, which could be relevant at higher research doses or in tissues with lower HGF expression where the compound-HGF interaction is less efficiently engaged. Systematic off-target profiling (radioligand binding panels, kinase selectivity panels) has not been published for Dihexa.

How It Compares

Dihexa vs. Semax

Semax (ACTH4-7 Pro-Gly-Pro) is the most commonly referenced comparator among intranasal cognitive peptides in the research literature. ^[13] Its mechanism involves induction of BDNF and VEGF expression via ACTH receptor-independent pathways and modulation of dopaminergic tone. Unlike Dihexa, Semax acts through the neurotrophin system upstream of receptor tyrosine kinase activation rather than through direct RTK pathway potentiation. The evidence base for Semax includes limited Russian-language clinical data (primarily acute stroke and cognitive enhancement trials with small sample sizes conducted in the 1990s-2000s), which gives it marginally more human-data context than Dihexa, though neither compound has undergone Western-standard Phase I-III trials.

From a practical research perspective, Semax's intranasal route and short plasma half-life (minutes) make it a fundamentally different pharmacological tool than Dihexa. For researchers interested in subacute or chronic synaptogenic effects requiring days-to-weeks of treatment, Dihexa's longer effective half-life and oral availability may be operationally preferable. For acute neuroprotection paradigms (e.g., ischemia-reperfusion in rodent models), Semax's rapid CNS delivery may be advantageous.

Dihexa vs. Cerebrolysin

Cerebrolysin is the most clinically advanced comparator, having been evaluated in multiple Phase II and III randomized trials for Alzheimer's disease and post-stroke cognitive impairment. ^[14] The compound is a complex mixture of low-molecular-weight peptides derived from porcine brain protein hydrolysis, and its mechanism is broadly described as neurotrophic-factor-mimetic, with effects on BDNF, NGF, and IGF-1 pathways. The clinical data on Cerebrolysin are modestly positive (statistically significant but clinically small improvements on ADAS-cog in some trials) and it is approved in several Eastern European and Asian markets for dementia.

The comparison with Cerebrolysin is useful in calibrating expectations for HGF/MET-targeting strategies. If a well-studied neurotrophic mixture like Cerebrolysin produces only modest clinical effects in Alzheimer's disease despite years of development, the bar for any single-mechanism neurotrophic agent including Dihexa is not low. Dihexa's mechanistic focus on HGF/MET is scientifically distinctive, but focus does not guarantee clinical superiority.

Dihexa vs. BPC-157

BPC-157 (body protection compound, pentadecapeptide) shares with Dihexa a pro-angiogenic and tissue-protective profile that creates theoretical oncologic concern, though the mechanisms differ: BPC-157 operates primarily through nitric oxide pathways and growth hormone receptor interactions rather than through MET. ^[15] Both compounds have substantial preclinical data without human clinical trial data, and both are available in oral and injectable research formats. BPC-157's evidence base is considerably broader in scope (gastrointestinal, musculoskeletal, and neurological models), while Dihexa's evidence base is more narrowly focused on cognitive and nerve-regeneration paradigms. See our BPC-157 review for a detailed comparison of that compound.

Where to Buy

Apollo Peptide Sciences is the vendor for this formulation. The 10 mg (60 capsule) unit is listed at $150.00. For the full vendor review, pricing history, and current availability, see our Dihexa 10mg product page, which links to the Apollo Peptide Sciences listing. The page template handles the affiliate routing; do not attempt to locate a direct vendor URL from this review.

Before ordering from any research-peptide supplier, researchers should review the vendor's CoA policy, their third-party testing program, and their shipping conditions for temperature-sensitive materials. Our supplier guide covers the criteria we use to evaluate research-peptide vendors, including CoA transparency, third-party analytical verification, and customer service responsiveness. We also maintain a disclosure page explaining our affiliate relationships and how they interact with our editorial independence.

FAQ